8BN Stock Overview Produces and supplies psilocybin, psilocin, other psychedelic substances, and functional mushrooms for health and wellness markets in Canada. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Optimi Health Corp. Competitors Price History & Performance
Summary of share price highs, lows and changes for Optimi Health Historical stock prices Current Share Price CA$0.13 52 Week High CA$0.31 52 Week Low CA$0.11 Beta 1.2 1 Month Change -6.34% 3 Month Change 5.56% 1 Year Change -40.09% 3 Year Change -51.28% 5 Year Change n/a Change since IPO -72.20%
Recent News & Updates
Optimi Health Corp. Completes Larger MDMA Capsule Batch to Date, Expands Stability Program Feb 01 Optimi Health Corp. Auditor Raises 'Going Concern' Doubt Jan 31
Optimi Health Corp. announced that it has received CAD 0.9735 million in funding Jan 29
Optimi Health Corp. Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand Jan 16
Optimi Health Corp. Announces First PTSD Patients Treated with MDMA Capsules in Australia Oct 24
Optimi Health Corp. Announces Chief Executive Officer Changes Oct 21 See more updates
Optimi Health Corp. Completes Larger MDMA Capsule Batch to Date, Expands Stability Program Feb 01 Optimi Health Corp. Auditor Raises 'Going Concern' Doubt Jan 31
Optimi Health Corp. announced that it has received CAD 0.9735 million in funding Jan 29
Optimi Health Corp. Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand Jan 16
Optimi Health Corp. Announces First PTSD Patients Treated with MDMA Capsules in Australia Oct 24
Optimi Health Corp. Announces Chief Executive Officer Changes Oct 21
Third quarter 2024 earnings released: CA$0.018 loss per share (vs CA$0.017 loss in 3Q 2023) Sep 01 Optimi Health Corp. announced that it expects to receive CAD 5 million in funding Aug 08
Second quarter 2024 earnings released: CA$0.016 loss per share (vs CA$0.014 loss in 2Q 2023) Jun 04
Optimi Health Receives Certificate of Analysis for Mdma 40Mg and 60Mg Gmp Capsules May 15
Optimi Health Corp. Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research May 10
Optimi Health Corp. Completes In-House Production of MDMA Active Pharmaceutical Ingredient Apr 16
Optimi Health Corp. Receives Finished Product Test Results and Certificate of Analysis for GMP Natural Psilocybin Extract Apr 02
First quarter 2024 earnings released: CA$0.014 loss per share (vs CA$0.015 loss in 1Q 2023) Mar 03
New major risk - Financial position Feb 28
New minor risk - Shareholder dilution Feb 26
Optimi Health Corp. announced that it expects to receive CAD 1.5 million in funding Feb 10
Optimi Health Corp. announced that it expects to receive CAD 1.5 million in funding Feb 09 Optimi Health Corp. announced that it expects to receive CAD 1.5 million in funding Feb 08
Full year 2023 earnings released: CA$0.06 loss per share (vs CA$0.094 loss in FY 2022) Jan 31
Optimi Health Corp., Annual General Meeting, Feb 22, 2024 Dec 23
Optimi Health Corp. Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing Nov 29
Optimi Health Corp. Announces Executive Changes Nov 08
Optimi Health Corp. Announces Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial Sep 15
Third quarter 2023 earnings released: CA$0.017 loss per share (vs CA$0.017 loss in 3Q 2022) Aug 23
Natural Health Grants Optimi Health Corp. Product Site License by Health Canada May 11
Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists Feb 08
Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL Feb 07
Optimi Health Corp. Announces Departs Michael Stier as Director Jan 12
Less than half of directors are independent Nov 16
Optimi Health Corp., Annual General Meeting, Jan 09, 2023 Nov 12 Optimi Health Corp. announced that it has received CAD 1.85 million in funding Oct 12
Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada Sep 23
Optimi Health Corp. Completes Larger Legal Natural Psilocybin Harvest Sep 10
Optimi Health Corp. Appoints Justin Kirkland as Chief Science Officer Aug 31
Optimi Health Corp. Appoints Jacob Safarik to its Board of Directors Aug 26
Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients Aug 11 Optimi Health Corp. Requests Approval to Manufacture Mdma, Other Synthetic Psychedelics Jun 21
Optimi Health Corp. Completes First Grow of Psilocybin Mushrooms
Less than half of directors are independent Apr 27
Optimi Health Corp. Launches E-Commerce Platform Featuring All-Natural Functional Mushroom Supplements Feb 24
Optimi Labs Inc. Gets Dealer’s License by Health Canada Feb 08
Optimi Health Corp., Annual General Meeting, Feb 24, 2022 Feb 02
Optimi Health Corp. Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent Jan 19
Optimi Health and Numinus Wellness Inc. Completes Pre-Clinical Trial Application Meeting Jun 16
Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application May 12
Optimi Health Corp. Receives Health Canada NPN Product Licenses in Preparation for Second Quarter of 2021 Sales Launch Mar 17 Shareholder Returns 8BN DE Food DE Market 7D 3.1% -2.9% 2.7% 1Y -40.1% -8.1% 17.0%
See full shareholder returns
Return vs Industry: 8BN underperformed the German Food industry which returned -8.3% over the past year.
Return vs Market: 8BN underperformed the German Market which returned 17% over the past year.
Price Volatility Is 8BN's price volatile compared to industry and market? 8BN volatility 8BN Average Weekly Movement 11.1% Food Industry Average Movement 4.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.1% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 8BN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8BN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Optimi Health Corp. produces and supplies psilocybin, psilocin, other psychedelic substances, and functional mushrooms for health and wellness markets in Canada. The company offers raw mushroom biomass, mushroom extracts, and mushroom supplements, as well as a range of manufacturing of drug products. It sells its products through Amazon marketplace and distributors/brokers, as well as online.
Show more Optimi Health Corp. Fundamentals Summary How do Optimi Health's earnings and revenue compare to its market cap? 8BN fundamental statistics Market cap €13.62m Earnings (TTM ) -€4.06m Revenue (TTM ) €262.16k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 8BN income statement (TTM ) Revenue CA$389.85k Cost of Revenue CA$670.03k Gross Profit -CA$280.18k Other Expenses CA$5.76m Earnings -CA$6.04m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.063 Gross Margin -71.87% Net Profit Margin -1,548.25% Debt/Equity Ratio 28.4%
How did 8BN perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/16 13:19 End of Day Share Price 2025/02/14 00:00 Earnings 2024/09/30 Annual Earnings 2024/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Optimi Health Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
